|
|
Article: Pioglitazone Enhances Glucose Tolerance in Type 2 Diabetes by Improving Suppression of Endogenous Glucose Production; Data show pioglitazone targets two defects associated with type 2 diabetes.
- Article from:
- PR Newswire
- Article date:
- June 14, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW ORLEANS -- NEW ORLEANS, June 14 /PRNewswire/ -- 10:00 a.m. CT -- In addition to increasing the body's sensitivity to insulin, pioglitazone HCl also helps suppress the amount of glucose the liver produces, according to findings presented today at the American Diabetes Association's 63rd Annual Scientific Sessions. Pioglitazone is an oral treatment for type 2 diabetes belonging to the thiazolidinedione (TZDs) class of drugs. It is known as an "insulin sensitizer" because it directly targets insulin resistance, a condition where the body does not effectively use the insulin it produces. The study presented today is the first of its kind to evaluate the mechanisms by ...